Ocugen (OCGN) Consolidated Net Income (2014 - 2026)
Ocugen's (OCGN) quarterly Consolidated Net Income came in at -$35.9 million in Q1 2026, down 131.98% YoY from $112.1 million in Q1 2025, and down 98.84% on a QoQ basis from -$18.0 million in Q4 2025.
Ocugen (OCGN) Consolidated Net Income (2014 - 2026) Analysis & Trends
Ocugen (OCGN) has 13 years of Consolidated Net Income data on file, last reported at -$35.9 million in Q1 2026.
- Quarterly Consolidated Net Income fell 131.98% year-over-year to -$35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$92.8 million (down 46.4% YoY) and the FY2025 annual result came in at -$198.0 million, down 14.43% from the prior year.
- Consolidated Net Income fell to -$35.9 million in Q1 2026, from -$18.0 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$13.0 million in Q3 2024 to a low of -$123.9 million in Q4 2023.
- A 5-year average of -$27.7 million and a median of -$21.0 million in 2024 frame the typical range for Consolidated Net Income.
- Annual changes were most pronounced in 2023 — Consolidated Net Income slumped 464.92% — and 2024, when it jumped 88.75%.
- Tracing OCGN's Consolidated Net Income over 5 years: stood at -$21.9 million in 2022, then tumbled by 464.92% to -$123.9 million in 2023, then jumped by 88.75% to -$13.9 million in 2024, then declined by 29.36% to -$18.0 million in 2025, then slumped by 98.84% to -$35.9 million in 2026.
- The last three Consolidated Net Income figures came in at -$35.9 million (Q1 2026), -$18.0 million (Q4 2025), and -$18.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ocugen | 457.71 Mn | 357.61 Mn | - | -26.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.33 Mn |
| Mar 31, 2026 | -35.86 Mn |
| Dec 31, 2025 | -18.03 Mn |
| Sep 30, 2025 | -18.73 Mn |
| Jun 30, 2025 | -20.14 Mn |
| Mar 31, 2025 | -15.46 Mn |
| Dec 31, 2024 | -13.94 Mn |
| Sep 30, 2024 | -12.98 Mn |
| Jun 30, 2024 | -20.99 Mn |
| Mar 31, 2024 | -18.41 Mn |
| Dec 31, 2023 | -123.94 Mn |
| Sep 30, 2023 | -16.87 Mn |
| Jun 30, 2023 | -28.17 Mn |
| Mar 31, 2023 | -22.85 Mn |
| Dec 31, 2022 | -21.94 Mn |
| Sep 30, 2022 | -21.92 Mn |
| Jun 30, 2022 | -27.15 Mn |
| Mar 31, 2022 | -33.50 Mn |
| Dec 31, 2021 | -14.58 Mn |
| Sep 30, 2021 | -10.76 Mn |